- Home
- GOSS vs ONDS Comparison
GOSS vs ONDS Comparison
Compare GOSS & ONDS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GOSS
- ONDS
- Stock Information
- Founded
- GOSS 2015
- ONDS 2014
- Country
- GOSS United States
- ONDS United States
- Employees
- GOSS N/A
- ONDS N/A
- Industry
- GOSS Biotechnology: Pharmaceutical Preparations
- ONDS Telecommunications Equipment
- Sector
- GOSS Health Care
- ONDS Telecommunications
- Exchange
- GOSS Nasdaq
- ONDS Nasdaq
- Market Cap
- GOSS 347.8M
- ONDS 1.4B
- IPO Year
- GOSS 2019
- ONDS N/A
- Fundamental
- Price
- GOSS $2.47
- ONDS $5.86
- Analyst Decision
- GOSS Strong Buy
- ONDS Strong Buy
- Analyst Count
- GOSS 4
- ONDS 3
- Target Price
- GOSS $8.50
- ONDS $4.67
- AVG Volume (30 Days)
- GOSS 3.1M
- ONDS 49.3M
- Earning Date
- GOSS 08-05-2025
- ONDS 08-12-2025
- Dividend Yield
- GOSS N/A
- ONDS N/A
- EPS Growth
- GOSS N/A
- ONDS N/A
- EPS
- GOSS N/A
- ONDS N/A
- Revenue
- GOSS $40,237,000.00
- ONDS $16,131,404.00
- Revenue This Year
- GOSS N/A
- ONDS $246.94
- Revenue Next Year
- GOSS $30.65
- ONDS $161.09
- P/E Ratio
- GOSS N/A
- ONDS N/A
- Revenue Growth
- GOSS N/A
- ONDS 75.16
- 52 Week Low
- GOSS $0.66
- ONDS $0.57
- 52 Week High
- GOSS $2.65
- ONDS $6.19
- Technical
- Relative Strength Index (RSI)
- GOSS 68.08
- ONDS 79.19
- Support Level
- GOSS $2.38
- ONDS $3.20
- Resistance Level
- GOSS $2.65
- ONDS $4.33
- Average True Range (ATR)
- GOSS 0.15
- ONDS 0.54
- MACD
- GOSS 0.03
- ONDS 0.17
- Stochastic Oscillator
- GOSS 76.67
- ONDS 89.02
About GOSS Gossamer Bio Inc.
Gossamer Bio Inc is a clinical-stage biopharmaceutical company. It focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology. The company pipeline products include Seralutinib, which address the cellular overgrowth, fibrosis, and vascular remodeling which underlie PAH (pulmonary arterial hypertension); GB004, for the treatment of inflammatory bowel disease, including ulcerative colitis and Crohn's disease; GB1275, for the treatment of oncology indications; and GB001, for the treatment of moderate-to-severe eosinophilic asthma.
About ONDS Ondas Holdings Inc.
Ondas Holdings Inc designs, develops, manufactures, sells, and supports FullMAX Software Defined Radio (SDR) technology in the United States, Israel, and India. The company operates in two business segments namely Ondas Networks and Ondas Autonomous Systems. The company generates maximum revenue from Ondas Autonomous Systems through the sales of the Optimus system and separately priced support, maintenance, and ancillary services related to the sale of the Optimus system.